Company (Location) |
Funding |
Amount (US$M) |
Type |
Details |
Date |
MARCH | |||||
Acadia Pharmaceuticals Inc. (San Diego) |
Michael J. Fox Foundation |
$0.322 |
Grant |
For further development of Nurr1-RXT selective agonists for Parkinson's disease |
3/28/12 |
Aeras (Rockville, Md.) |
Bill and Melinda Gates Foundation |
$220 |
Grant |
For the development of vaccines against tuberculosis |
3/16/12 |
Avaxia Biologics Inc. (Lexington, Mass.) |
National Institute of Diabetes and Digestive Kidney Diseases |
$1.5 |
Phase II SBIR grant |
To develop an antibody therapeutic for inflammatory bowel disease |
3/20/12 |
Biovista Inc. (Charlottesville, Va.) |
CFIDS Association of America |
ND |
Grant |
To identify nonobvious mechanisms of chronic fatigue syndrome and potential drug repositioning candidates that will advance objective diagnosis and treatment |
3/7/12 |
Domain Therapeutics SA (Strasbourg, France) |
French government |
€5.1 ($6.7) |
Grant |
For the ATHOS project, focused on orphan G protein-coupled receptors as a target for schizophrenia drugs |
3/14/12 |
Emergent BioSolutions Inc. (Rockville, Md.) |
National Institute of Allergy and Infectious Diseases |
ND |
Multi-year grant |
To develop the tuberculosis vaccine MVA85A |
3/26/12 |
GenVec Inc. (Gaithersburg, Md.) |
National Institute of Allergy and Infectious Diseases |
$0.6 |
SBIR grant |
To support the firm's malaria vaccine program |
3/27/12 |
Hadasit Bio-Holdings Ltd. (Jerusalem) |
Israeli Ministry of Industry and Commerce, Office of the Chief Scientist |
NIS6.1 ($1.6) |
Grant |
To support product development and advance clinical trials |
3/14/12 |
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.) |
Department of Defense |
ND |
SBIR grant |
To advance the development of a low-cost, non-invasive surface electroporation delivery device and test its use in combination with Inovio's synthetic DNA vaccines against viruses with bioterrorism potential |
4/3/12 |
Medicyte GmbH (Heidelberg, Germany) |
BMBF |
€0.3 ($0.397) |
Three-year grant |
To develop culturing methods of human hepatocytes for use in cell-based therapies |
3/6/12 |
SK Biopharma-ceuticals (Seoul, South Korea) |
Korea Drug Development Fund |
ND |
Grant |
To support clinical development for the next three years of Phase II trials for YKP3089 for refractory epilepsy |
3/5/12 |
APRIL | |||||
BioMarCare Technologies Ltd. (subsidiary of Hadasit Bio-Holdings Ltd.; Jerusalem) and Ariadne Inc. (Wilmington, Del.) |
Binational Industrial Research and Development Foundation |
$0.9 |
Grant |
To support a joint project to develop biomarkers that predict response or lack of response to drugs that inhibit the EGF receptor; BioMarCare will be responsible for developing the test while carrying out a clinical trial in Israel |
4/13/12 |
Catabasis Pharmaceuticals Inc. (Cambridge, Mass.) |
Muscular Dystrophy Association |
$0.12 |
Grant |
To test CAT-1004 and CAT-1040 in a Duchenne's muscular dystrophy mouse model |
4/5/12 |
Islet Sciences Inc. (New York) |
National Institutes of Health and the Iacocca Foundation |
$2.1 |
Grants |
Islet's subsidiary DiaKine Thera-peutics Inc. received $1.83M from NIH and $250,000 from the Iacocca Foundation to support its work in diabetes |
4/10/12 |
KineMed Inc. (Emeryville, Calif.) |
National Institutes of Health |
ND |
Grant |
For manufacturing, formulation and investigational new drug-enabling safety studies of FX-5A, an ApoA-I mimetic designed to reverse atherosclerosis and heart disease |
4/11/12 |
NeurOp Inc. (Atlanta) |
National Institutes of Health |
$0.7 |
Grant |
To support research in new schizophrenia treatments |
4/12/12 |
Thermalin Diabetes LLC (Cleveland) |
National Institutes of Health |
$4.5 |
Grant |
To continue development of its insulin analogues |
4/30/12 |
to-BBB Technologies BV (Leiden, the Netherlands) |
Michael J. Fox Foundation |
ND |
Grant |
For preclinical research related to its Parkinson's disease candidate, 2B3-201 |
4/18/12 |
Winston Pharmaceuticals Inc. (Vernon Hills, Ill.) |
National Institutes of Health |
$0.375 |
Phase I SBIR grant |
To support the development of Civamide, a TRPV-1 receptor modulator, in postherpetic neuralgia of the trigeminal nerve |
4/10/12 |
MAY | |||||
ActiveSite Pharmaceuticals Inc. (Berkeley, Calif.) |
National Eye Institute |
$1.3 |
SBIR grant |
To support its program in orally active plasma kallikrein inhibitors for diabetic macular edema |
5/8/12 |
GenVec Inc. (Gaithersburg, Md.) |
National Institute of Allergy and Infectious Diseases |
$0.59 |
SBIR grant |
For its respiratory syncytial virus vaccine program |
5/4/12 |
Halo Therapeutics LLC (Newton, Mass.) |
12 nonprofit foundations dedicated to muscular dystrophy |
$1.1 |
Grant |
To support its Phase II trial of HT-100 for Duchenne's muscular dystrophy |
5/23/12 |
ImmuVen Inc. (Champaign, Ill.) |
National Institute of Allergy and Infectious Diseases |
$1.68 |
Phase II SBIR grant |
For continuing development of IMV0123 for superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcus aureus |
5/2/12 |
Khondrion BV (Nijmegen, Germany), Radboud University Nijmegen Medical Center, Pharmacelsus GmbH (Saarbruecken, Germany) and ElexoPharm GmbH (Sarbruecken, Germany) |
German Federal Ministry of Education and Research |
€2.1 ($1.6) |
Eurostars grant |
To support discovery of treatments for mitochondrial diseases |
5/22/12 |
Kineta Inc. (Seattle) |
National Institute of Allergy and Infectious Diseases |
$8.1 |
Grant |
To support its collaboration with the University of Washington and the University of Texas Medical Branch at Galveston to develop drugs for infectious diseases |
5/9/12 |
Medgenics Inc. (Misgav, Israel) |
Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of Israel |
NIS8.1 ($2.2) |
Grant |
To cover expenses for the 12-month period from October 2011 through September 2012 to support further research and clinical development of the tissue-based Biopump platform technology in a number of indications including anemia and hepatitis |
5/10/12 |
Northwest Biotherapeutics Inc. (Bethesda, Md.) |
Saxony Development Bank |
$5.5 |
Grant |
To help fund a clinical trial for DCVax-L for glioblastoma multiforme at up to 30 sites in Germany |
5/2/12 |
Pluristem Therapeutics Inc. (Haifa, Israel) |
Office of the Chief Scientist within the Israeli Ministry of Industry, Trade and Labor |
NIS11.8 ($3.1) |
Grant |
To fund research and development expenses for Pluristem's PLX cells drug delivery platform from March 2012 to December 2012 |
5/1/12 |
Profectus BioSciences Inc. (Baltimore), Galveston National Laboratory at the University of Texas Medical Branch at Galveston |
National Institute of Allergy and Infectious Diseases |
$5.4; $5.6 |
Five-year grant |
To support development of a trivalent vaccine to protect against infection with all major strains of Ebola and Marburg viruses; grant to Profectus for the preclinical development of Hendra virus soluble G as a vaccine for use in humans against either Nipah or Hendra virus infection |
5/3/12; 5/10/12 |
Prothix BV, Bioceros BV and University Medical Utrecht (all of Utrecht, the Netherlands) and Antitope Ltd. (Cambridge, UK) |
Eureka |
€1.6 ($2) |
Eurostars grant |
For the preclinical development of a monoclonal antibody as a novel anticoagulant |
5/23/12 |
Pulmotect Inc. (Houston) |
Cancer Prevention & Research Institute of Texas |
$7.1 |
Grant |
To advance PUL-042, a product to protect chemotherapy patients from infection |
5/10/12 |
ResveraGen BioPharma (Rockville, Md.) |
Muscular Dystrophy Association |
$1.5 |
Grant |
To develop a dissociative glucocorticoid as a therapy for Duchenne's muscular dystrophy |
5/4/12 |
JUNE | |||||
BrainStorm Cell Therapeutics Ltd. (Tel Aviv, Israel) |
Israel's Office of the Chief Scientist |
$0.35 |
Grant |
BrainStorm received the first installment of about $350,000 of the 2012 grant; the total yearly grant is worth $1.1M, and will go toward development of NurOwn therapy for ALS using autologous adult stem cells |
6/15/12 |
Circassia Ltd. (Oxford, UK) |
National Institutes of Health |
$6.4 |
Grant |
Given to Mark Larche, of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia's ToleroMune allergy therapy |
6/8/12 |
ERYtech Pharma (Lyon, France) |
OSEO's Strategic Industrial Innovation program |
$8.65 |
Grant |
To lead the eight-year TEDAC project focused on developing enzymes targeting chemo- and radio-resistant cancers, as well as tools to identify responders and enable personalized treatment |
6/6/12 |
Exonhit SA (Paris) |
OSEO's Strategic Industrial Innovation program |
$2.4 |
Grant |
To develop a companion diagnostic with ERYtech Pharma's enzymes targeting chemo- and radio-resistant cancers |
6/5/12 |
iCo Therapeutics Inc. (Vancouver, British Columbia) |
National Research Council of Canada |
$1.1 |
Grant |
To support its oral Amphotericin B delivery system as a treatment for patients with HIV |
6/1/12 |
Innovimmune Biotherapeutics Inc. (New York) |
National Institute of Allergy and Infectious Diseases |
$0.6 |
SBIR grant |
For development of its macrophage migration inhibitor factor for rheumatoid arthritis |
6/14/12 |
InVitria (division of Ventria Bioscience; Fort Collins, Colo.) |
National Institute of Allergy and Infectious Diseases |
$1.5 |
SBIR grant |
To develop an animal-free system for cell-based vaccine production |
6/5/12 |
Isogenica Ltd. and Biolauncher Ltd. (Cambridge, UK) |
Cresset Group (Welwyn Garden City, UK) |
£1 ($1.5) |
Grant |
To develop a highly scalable approach to small-molecule drug discovery |
6/7/12 |
KineMed Inc. (Emeryville, Calif.) |
The Michael J. Fox Foundation |
$1.2 |
Grant |
To be used for the ongoing development of validated biomarkers for Parkinson's disease |
6/28/12 |
NeoStem Inc. (New York) |
National Institute of Allergy and Infectious Diseases |
$0.595 |
Two-year grant |
To support studies to investigate the potential of very small embryonic-like stem cells as a countermeasure to radiological and nuclear threats |
6/26/12 |
Sanaria Inc. (Rockville, Md.) and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park |
National Institute of Allergy and Infectious Diseases |
$3 |
SBIR grant |
To fund research and development to genetically engineer mosquitoes that produce large numbers of parasites for the company's malaria vaccine manufacturing process |
6/15/12 |
Sirnaomics Inc. (Gaithersburg, Md.) |
National Institutes of Health |
ND |
SBIR grant |
To support development of its small interfering RNA therapeutic product STP705 to improve skin wound healing |
6/26/12 |
Soligenix Inc. (Princeton, N.J.) |
National Institute of Allergy and Infectious Diseases |
$0.6 |
SBIR grant |
To support additional preclinical development of OrbeShield in gastrointestinal acute radiation syndrome |
7/18/12 |
Sorrento Therapeutics Inc. (San Diego) |
National Institute of Allergy and Infectious Diseases |
ND |
STTR grant |
To support the company's program to develop human antibody therapeutics against S. aureus infections |
6/11/12 |
Telormedix SA (Bioggio, Switzerland) and Foamix Ltd. (Rehovot, Israel) |
European Eurostars Programme |
€0.95 ($1.2) |
Grant |
To coordinate a two-year international research project aimed at developing a skin cancer topical treatment based on a foam formulation of Telormedix' candidate TMX-202 |
6/5/12 |
JULY | |||||
Biodel Inc. (Danbury, Conn.) |
National Institutes of Health |
$0.582 |
SBIR grant |
For the development of concentrated ultra-rapid-acting insulin formulations for use in an artificial pancreas, also known as a closed loop pump system |
7/27/12 |
Oxford BioMedica plc (London) |
Foundation Fighting Blindness |
$0.125 |
Grant |
To support the opening of a second trial site in Paris for the UshStat Phase I/IIa study |
7/24/12 |
XenoPort Inc. (Santa Clara, Calif.) |
Michael J. Fox Foundation for Parkinson's Research |
$0.347 |
Grant |
To support preclinical studies exploring the ability of XP23829 |
7/12/12 |
Notes: ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. Currency conversions reflect values at the time of a deal's announcement. SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. |